Sector Gamma AS Raises Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sector Gamma AS raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,316 shares of the medical equipment provider’s stock after purchasing an additional 1,354 shares during the quarter. Lantheus makes up about 0.8% of Sector Gamma AS’s holdings, making the stock its 29th biggest holding. Sector Gamma AS owned about 0.08% of Lantheus worth $3,244,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its holdings in shares of Lantheus by 1,828.2% during the 3rd quarter. SG Americas Securities LLC now owns 28,711 shares of the medical equipment provider’s stock valued at $1,995,000 after buying an additional 27,222 shares in the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Lantheus during the 3rd quarter valued at $68,000. Peregrine Capital Management LLC boosted its holdings in shares of Lantheus by 8.3% during the 3rd quarter. Peregrine Capital Management LLC now owns 268,110 shares of the medical equipment provider’s stock valued at $18,628,000 after buying an additional 20,554 shares in the last quarter. Linden Thomas Advisory Services LLC bought a new stake in shares of Lantheus during the 3rd quarter valued at $1,266,000. Finally, Deltec Asset Management LLC bought a new stake in shares of Lantheus during the 3rd quarter valued at $902,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Truist Financial restated a “buy” rating and set a $82.00 target price (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. JMP Securities reaffirmed a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Finally, B. Riley upped their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $104.71.

Lantheus Stock Performance

Lantheus stock traded up $0.36 during midday trading on Friday, hitting $65.56. The stock had a trading volume of 584,631 shares, compared to its average volume of 638,384. The firm’s fifty day moving average is $61.62 and its two-hundred day moving average is $62.74. The company has a market capitalization of $4.49 billion, a PE ratio of 14.13 and a beta of 0.53. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $100.85. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. On average, research analysts forecast that Lantheus Holdings, Inc. will post 5.96 EPS for the current year.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders sold a total of 94,545 shares of company stock valued at $6,169,936 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.